Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Heather Davis September 27, 2011 Ottawa, Canada Biotech to Big Pharma Personal Experience.

Similar presentations


Presentation on theme: "1 Heather Davis September 27, 2011 Ottawa, Canada Biotech to Big Pharma Personal Experience."— Presentation transcript:

1 1 Heather Davis September 27, 2011 Ottawa, Canada Biotech to Big Pharma Personal Experience

2 2 Coley’s founding technology: CpG oligonucleotides TLR9 agonists Initial discovery was finding the molecular pattern in bacteria and DNA viruses that turns on the immune system shortly after infection  Specific DNA sequence known as “CpG motifs”  Activate through Toll-like receptor 9 found on certain immune cells Coley discovered and developed synthetic CpG drugs Platform technology with wide potential applications  Adjuvants for vaccines Made current vaccines work better – can use lower doses (antigen sparing important during pandemic) Allowed development of new types of therapeutic vaccines  Cancer immunotherapy  Treatment for asthma and allergy

3 3 Coley’s TLR Therapeutics™ Platform Progression Coley’s Technologies CpG TLR9 AGONISTS  Cancers –Solid –Hematologic  Asthma & Allergy  Vaccine Adjuvant Original technology Licensed from founders’ academic institutions RNA AGONISTS SMALL MOLECULES TLR7, TLR8  Cancers  Infectious Diseases Licensed from 3M after much of original technology licensed out ANTAGONISTS TLR7, 8, 9  Autoimmune and Inflammatory Disorders –Lupus –RA New technology Developed in-house

4 4 4 Coley’s Timeline Coley acquired by Pfizer Coley incorporated (1997 USA, 2001 Canada) Incubated in Krieg & Davis academic labs until 2003 CLINICAL 1 st three CpG clinical (vaccine) studies run from Ottawa LICENSING DEAL Cancer immune therapy clinical trials Hepatitis C immune therapy Lupus/RA immune therapy PRE-CLINICAL CpG as vaccine adjuvant Oncology immune therapy & therapeutic vaccines Autoimmunity Co-founded by Art Krieg (U Iowa), Heather Davis (U Ottawa / OHRI) and Joachim Schorr (Qiagen)

5 5 Licensing Deals & Outcomes PARTNERIndicationTotal Deal Milestones Received by 2007 GSKID Vaccines$62 M$11.5 M GSKCancer Vaccines$44 M$9 M NovartisVaccines$35 M$1.8 M MerckVaccines$33 M$4 M OtherOther vaccines$35 M$21 M Sanofi aventis Asthma, allergic rhinitis $265 M$14 M PfizerCancer therapy$515 M$65 M Took to Phase 1 – no clinical activity since In Phase 3 testing Took to Phase 1 – cancelled license No clinical testing Emergent – completed Phase 1, ongoing activities Took to Phase 1 – cancelled license Phase 3 trial failed

6 6 How to succeed in biotech Founder characteristics Secure financing Recruit senior management Valuable technology, protected by IP Luck & timing

7 7 Founder characteristics Hard working, driven Adaptable  Able to wear many hats  Successful transition from academia to corporate world requires thinking differently Hard working

8 8 Securing financing Coley had 1 year funding from founder Initial venture funding was Swiss / German investors who had previously invested in corporate founder Subsequent rounds introduced US investors No Canadian VC’s ever participated  Too late  Expected too much control for their investment

9 9 Recruit senior management Founders rarely make good senior managers Coley benefitted for 3 years by using senior management of another company Coley later hired own management team  Huge advantage having head office in Boston area Candidates with senior drug development experience are relatively rare in Canad  Critical hires since each represents a single point of failure  Drug development complex and only learned through experience Senior executives coming from Big Pharma sometimes couldn’t scale down to biotech appropriate activities

10 10 Valuable technology Technology must actually work  Positive clinical data trumps all  Selling technology on mouse data possible, but typically brings low value or back-loaded deals Platform technologies have greater chance to succeed Need to know when to let go  Unrealistic for biotech company to expect to develop pharmaceutical product to market IP protection critical  Needs to be broad in scope and geography  IP protection costs escalate rapidly after provisional filing – difficult for academic unit to sustain until alternate financing secured

11 11 Wild cards Luck Timing


Download ppt "1 Heather Davis September 27, 2011 Ottawa, Canada Biotech to Big Pharma Personal Experience."

Similar presentations


Ads by Google